a and Co-Chair business our for you year. session. XXXX Chief Today, the Commercial appointed Uecker, Mike Kevin results. I'll then Board; be earnings call thank of President Duggan, Director; me and will in this of will join Chief Officer second President Pulse progress, Koffler, and Vice continued of May us. Danahy, and for Officer, Technology first financial since and certain provide everyone, Pulse question-and-answer afternoon, Finance, on Then I'm Bob glad review to being quarter Darrin joining my Good on Biosciences CEO our of updates
why any I pioneering than that Pulse. devices. for devices To throughout and the I Ablation career. on begin, been has years, medical worked years the space XX to called XX nano-PFA medical potential last want believe of time briefly innovation cardiology I've spent more the approach device than Field in on Pulse's joined with my describe to I focusing other transformative I've Pulsed more my be majority
When the day, improve body treatments having and that nano-PFA these the supplant to has fact of kill many radiation in approaches other opportunity heat, treatments, all cells to use cold, you patients' undesirable Pulse many currently perhaps, and compete and to translates that to the available some even consider the significantly currently available that with, the lives. potential
potential even showing better the kill clinically. cold, studied and, way micro-PFA. This Pulse will radiation does moment, great the a we being product a core in promise it It's lines of is heat, is currently has X because cells in what possible as than in to and nano-PFA currently describe available the
Beyond I know-how. these for lines, products the multiple care Energy nano-PFA with of that standard to has other believe solidly and property X protected the or states technology across of intellectual and current potential disease disorders is body. The human the the product advance treatment
fantastic employees the alongside stakeholders the great support patient-focused, The transparent. and of is true The of culture and a Pulse is work last and Pulse to with Pulse joined It's I privilege associated reason team. because Pulse. results-oriented
technology. team is advancing next-generation this rapidly nano-PFA Pulse
the and technology the bringing nano-PFA novel on Biosciences all in expertise, scientific technology, adoption is have drive We eruptive Pulse to patients. pioneer property product including the focusing know-how. foundational organization elements industry of intellectual place to and its
a initial bakes of of Since preclinical Pulse decade treated tissue Pulse's nano-PFA the strong at using pre-company energy safety founding has dermatological the the back includes nano-PFA scientific amounts This the generated system working genesis body. human approximately the ago, of types clinical effects of in XX lesions approximately date, with X,XXX commencing company. human and differentiated data, profile. another for across skin years demonstrating different our To the massive CellFX
preclinical tissue. effects of Pulse library the images during largest numerous the types of has of knowledge, delivery various my To high-quality parameters nano-PFA on energy
scientific development could and time lead solid product to clinical Importantly, accelerated lines. foundation this
We experiences path where epicardial outcomes. to ablation tissue these currently focused In commercializing available ablation. the terms endocardial ablation, improve overall currently the areas developing devices are in soft has potential significant of each on products there upon categories, and surgical and unmet for patient of clinical of X to user catheter or need are nano-PFA
performance bringing the as product, demonstrating to and using approach nano-PFA data a differentiated nano-PFA more more from is general multiple to compete to in allow will and pathways, awareness streamlined of reimbursement regulatory well believe we way and produce developing review clearly clinical point compelling investing of products to in science compelling performance in to each Our wide markets view. to understanding clinical ultimately products a the well us of competitive lead demonstrate as
important heavily we with our at may classification invest Consistent with XXX(k)s request clinical that application. currency to pathways Clinical pathways de with to compelling products us to continue regulatory our data an be indications label include In PMA for clinical you. these in will Pulse. U.S., plan pursue and allow data is or specific data, so-called novo plan to the
will indication. this vary by And
the as more benefits. approval In time part while indications seeking taking regulatory process, general, following has specific the labeled sometimes of
clinical profile. patients the evidence in stakeholders other gives and confidence gathered First, increased and the safety device's clinicians, effectiveness
will treatment tool than Second, type, that general tissue a specific indication allow general statement. the option that's as only as it device and a a marketing rather the supports for
well indication and use in well-trained a and train and And democratization third, for market, market specific penetration is permit of adoption will generally as when the clinician it to enable more the as adoption device flexibility approved hands. quicker that can sell users
Pulse. extremely is This exciting We second a time for very quarter. productive an had
fibrillation in have soft receiving enrolling FDA's completing FDA, a and Rhythm live presenting Some devices, in following the and ablation for for U.S. from our a first or May. major case program surgery Designation cases XXX AF the at the delivered meeting TAP on with Breakthrough progress cases atrial with patient include: in first-in-human FDA Society key a the company's system we catheter U.S. completing highlights our tissue prestigious atrial X cardiac fibrillation clearance, Heart Device
We also moved office, leadership Miami, the while our significantly our successful headquarters rights QX. sheet strengthened Florida, team, Hayward our which through in balance expanded and to maintaining early our offering, transacted
offering $XX As exercise know, to additional of rights the the up issued you may warrants in the an bring company into million. could
half redeem these to the potential days. if up of trading consecutive more to our raise the if price $XX.XX warrants, warrants at with $XX redeem of the to our for for million with price or $XX share ability XX consecutive raise potential ability share or million company an to is Notably, these to the has to days as at second above half as XX the $XX trades up well additional the volume-weighted volume-weighted
regulatory I on in tissue along clinical will involving some thyroid, and our details tissue as such applications. a the progress, of other well ablation soft into many procedures, providing as broad liver, significant the body. our with Physicians parts Starting now of near-term dive ablation array those goals. with more as soft utilize breast
nano-PFA for soft nonthermal streamlined, a empowers to we clinical procedure delivered nodules promising has our via The ablation, needle achieve electrode, initial minimally while call compared benign clinicians invasive percutaneous of which electrodes. thyroid Nano-PFA results surgical needle tissue in to the the ablation potential resection. targeted CellFX percutaneous the very offering
our the in X sites system United performed treatments have of XX-day and we at date, To sites agreement. States, placed under a the initial have no-cost, these patient and evaluations system evaluation
product. some details our soft on provide additional background ablation tissue me Let
tissue FDA clearance U.S. U.S. our procedures received commercialization of surgical program. soft nano-PFA XXX(k) we in procedures. March, In use our intraoperative part pilot for system in as followed This the percutaneous was in and for the May by ablation novel of first
received the second gained plan experience of needle, the FDA additional patients. customers investigator-sponsored treatment and for program, we experience. under we with data our In will research clinical We to to being clearance for a addition options believe provide ablation pilot increased clinical their to size which support gather this also recently
a the the labeling we thyroid of order by clinical a specific early experience, presented for indication this designing Informed nodules. study in treatment clinical to FDA are achieve pivotal benign
As further they and we high-quality I mentioned novel devices. this in on and clinical investing unlock our pathways, believe we earlier for are on focused opportunities will call, regulatory
to to half to expect the trial treatment benign of pivotal nodules. in XXXX the a a in be of first clinical initiate thyroid indication for a We labeling position support specific
Looking to forward ahead, proprietary have additional we sharing updates soft in the look our progress for device plans tissue and our future. on ablation
a standard endocardial PFA rapidly represents of treat established That adopted leads AF a fibrillation or is therapy. surgical used to such catheter-based and for technologies as AF. breakthrough irregular Ablation epicardial of an in as ablation. our ablation care being treatment or us atrial is the to heartbeats
of second long, millionth faster, a in operates to the my are hence in which However, micro-PFA, microseconds, energy the speed and treatment the electrical currently of or PFA compared provide has our of nanosecond much to typically of pulses potential best-in-class clinical operates nano-PFA. technology nano-PFA, available AF. opinion, nano-PFA ease less each which to and than X tens hundreds that is the performance the name In use, next-generation delivers
Committee we have a call, Since Netherlands an excitingly, to from first-in-human patients. in now the have first earnings the received successfully the last study. company's conduct Ethics approval feasibility we And X treated
went procedures initial well. Our
includes to at This to and information We device. are our isolation chronic this treatment. on is patients approximately post study first-in-human months catheter-based evaluating and enroll study to confirm to endocardial X an or mapping efficacy designed effectiveness provide XX up of using safety feasibility multicenter by
unique received device. the clinical Designation The review application for the U.S., In of FDA prioritized addition pleased to Pulse to future nano-PFA. the have milestone for Designation Device Breakthrough will FDA. the an approval FDA a more follow-up. of the is the premarket emphasizes we from The In Device this benefits study provide granted by traditional are Breakthrough with designation and exciting potential
providing pathway. to Since our TAP also Designation, enrolled should and clinical was development medical to the additional devices to developers successfully with health early, program U.S. TAP parties expedite the Pulse FDA by and importance. of in communications Device which provide like created and have public opportunities with program, we The innovative the receiving of FDA's frequent regulatory expedite other Breakthrough engagement key strategic FDA's patient access for devices facilitating
intend to to pathway FDA for PMA opposed approved, as States approval early As PMA commercialize for United cardiac our a plan FDA fibrillation. we the application surgical Once we the route. treatment market to system now XXX(k) to nano-PFA the announced in atrial pursue July, as in
we determine will XXXX. and our further the near application for IDE study details time early PMA pathway, pivotal expect the to design future. pivotal in the to trial with clinical the FDA a present line. Discussions study FDA support ultimately the commence We the our to study plan in of To clinical
to Now our moving on applications. AF catheter-based endocardial
through applications and endocardial development Our third under delivering treatment a AF. next-generation is also nano-PFA to XXX for currently Cardiac on our Catheter product focused technology is
first where in efficacy of feasibility clinical the study safety and underway investigating in-human Our is Prague, we performance. are catheter's
have of to approval patients. enrollment XX pleased from XX are study this to expanded We for
catheter's times ease use, The in isolate to were patients. the pulmonary treated first of case veins, XX encouraging all very and ability the acutely
treatments already cohort. this We in XX-patient commenced have additional
In and clinical expanded outcomes. Prague, year. EU addition feasibility the this a X to other their the pivotal well-known clinical begin our the feasibility in indication add and aligning IDE additional is feedback expanded prestigious a to With studies, the in to sites U.S. our to next receiving pivotal propose these it pivotal experience design for intend to experiences we first-in-human FDA study final gather protocol, on of clinical sometime clinical results we study will and to on intention clinical the study study user and
the the we our are Altogether, effective safe across we device by X PMA treatments foundation Once future a the holds excited made providing and clinical in potential are and states study significant for across disease the provide completed, pivotal encouraged the by successfully submission. for devices, would progress each body.
of and further a oversubscribed in expenses readiness of million approximately our submissions development, novel proceeds to July. the rights commercial was provided the less devices, and clinical regulatory and offering X To rights $XXX,XXX. completed We're we future product that related offering $XX gross fundraising offering support of encouraged
the $XX of To serve off alongside of are LaViolette million. Pulse the quarter exciting of receive other and Co-Chairman, exercise that has Co-Chairman Pulse, to announce few Board what we Biosciences' warrants, proceeds very to past been up will thrilled Upon appointed Paul our company weeks all has the Duggan. Director. Bob He of additional could been cap for a
know confident we global work I've insights. excited he a known additive Paul I adoption. to and over highly successfully for He to his team. I'm We're extremely has and will through from with him, decade, scaled cardiology of franchises driving invaluable some be the benefit will medtech technology innovative our largest greatly
the over some financial second for Now quarter I'll XXXX. pass the provide to results of Koffler call Mike to
